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Abstract
Background: MUC5AC is a secretory mucin normally expressed in the surface muconous cells of stomach and 
bronchial tract. It has been known that MUC5AC de novo expression occurred in the invasive ductal carcinoma and 
pancreatic intraepithelial neoplasm with no detectable expression in normal pancreas, however, its function remains 
uncertain. Here, we report the impact of MUC5AC on the adhesive and invasive ability of pancreatic cancer cells.
Methods: We used two MUC5AC expressing cell lines derived from human pancreatic cancer, SW1990 and BxPC3. 
Small-interfering (si) RNA directed against MUC5AC were used to assess the effects of MUC5AC on invasion and 
adhesion of pancreas cancer cells in vitro and in vivo. We compared parental cells (SW1990 and BxPC3) with MUC5AC 
suppressed cells by si RNA (si-SW1990 and si-BxPC3).
Results: MUC5AC was found to express in more than 80% of pancreatic ductal carcinoma specimens. Next we 
observed that both of si-SW1990 and si-BxPC3 showed significantly lower adhesion and invasion to extracellular matrix 
components compared with parental cell lines. Expression of genes associated with adhesion and invasion including 
several integerins, matrix metalloproteinase (MMP) -3 and vascular endothelial growth factor (VEGF) were down-
regulated in both MUC5AC suppressed cells. Furthermore, production of VEGF and phosphorylation of VEGFR-1 were 
significantly reduced by MUC5AC down regulation. Both of si-SW1990 and si-BxPC3 attenuated activation of Erk1/2. In 
vivo, si-SW1990 did not establish subcutaneous tumor in nude mice.
Conclusions: Knockdown of MUC5AC reduced the ability of pancreatic cancer cells to adhesion and invasion, 
suggesting that MUC5AC might contribute to the invasive motility of pancreatic cancer cells by enhancing the 
expression of integrins, MMP-3, VEGF and activating Erk pathway.
Background
Pancreatic cancer has a poor prognosis; the 5-year sur-
vival rate in only 3% and the median survival rate is only 6
months[1]. It is also associated with aggressive cancer
cells, and metastatic disease that results from a lack of
early-stage diagnostic methods and effective therapies.
Adhesiveness and invasiveness of cancer cells play a cen-
tral role in pancreatic cancer progression [2,3]. Mucins
are highly glycosylated glycoproteins that are the major
components of the viscous mucous gel covering the sur-
face of epithelial tissues [4]. Changes in mucin expression
or glycosylation accompany the development of cancer
and influence cellular growth, differentiation, transfor-
mation, adhesion, invasion and immune surveillance [5].
Several papers have described the relationship between
mucin and pancreatic cancer, for example, de novo
expression of MUC5AC frequently occurs in intraductal
papillary mucinous tumors and pancreatic adenocarci-
noma [6-8], while Takikita et al. reported that borderline
statistically significant associations are seen between
expression of MUC5AC and shorter survival time in
patients with pancreatic cancer [8]. However, the func-
tion of MUC5AC remains uncertain. In this study, we
examined the impact of MUC5AC in a human pancreatic
cancer cell line.
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Small interfering RNA has recently been developed as a
powerful tool to suppress the expression of specific gene
products [9-11]. Previous studies on MUC1 suppression
[10-12] in lung, breast and pancreatic cancer cells
reported increased sensitivity to genotoxic drugs both in
vitro  and  in vivo [11]. We down-regulated MUC5AC
expression by siRNA and investigated the effects on the
malignant and metastatic potential of human pancreatic
cancer cell lines, SW1990 and BxPC3.
Methods
Cell lines and culture conditions
The human pancreatic cancer cell lines of SW1990,
BxPC3 and PCI-64 were cultured in Dulbecco's modified
Eagle's medium containing 10% fetal bovine serum, as
described previously [13]. The stable cell line si-SW1990
and si-BxPC3, created by siRNA transfection of parental
cells respectively, was maintained in the above medium
containing 500 μg/ml Geneticin (Invitrogen Japan, Tokyo,
JAPAN). Cells were cultured at 37°C under 5% CO2 in
incubators with 100% humidity.
Immunohistochemistry
Paraffin-embedded specimens from 100 patients with
pancreatic ductal carcinoma who underwent resection at
Department of Surgical Oncology, Osaka City University
Hospital from 1995 to 2007 were stained with anti-
MUC5AC monoclonal antibody (abcam, USA) according
to the manufacture's protocol.
siRNA design
The design of 19 nucleotide target sequences were based
on a computer algorithm and 5'-GCCACCGCTGCGGC-
CTTCTTC-3' was selected as the target sequence. These
were separated by a nine-nucleotide noncomplementary
spacer (5'-TTCAAGAGA-3') from the reverse comple-
ment of the same 19-nucleotide sequence.
For preparation of recombinant plasmids, oligonucle-
otides (64 bp) were ligated into the mammalian expres-
sion vector, pSilencer 3.1-H1 neo (Applied Biosytems
Japan, Tokyo, JAPAN) at the BamHI and HindIII cloning
sites. Recombinant MUC5AC-pSUPER gfp-neo con-
structs were used to transform Escherichia coli DH5,
which were selected on ampicillin-agarose plates and ver-
ified by sequencing.
Cell proliferation assay
Cell proliferation was determined by the 3H-thymidine
uptake assay. After 24 h or 48 h of incubation, radioactiv-
ity was measured using cell harvester and counters.
Experiments were performed in triplicate, and values are
expressed as cpm/well.
Adhesion assay
The adhesion assay was done as described before [14].
Briefly, A 96-well microtiter plate was coated with Matri-
gel (2 μg/well), laminin (4 μg/well) and fibronectin (4 μg/
well). Cancer cells (4 × 105) were then seeded onto these
components. No chemicals for extracellular stimulation
were added. Cells were allowed to adhere to each well for
30 min at 37°C and were then gently washed three times
with PBS. The adhesive cancer cells to extracellular com-
ponents were evaluated by 3-(4, 5-dimethylthiazol-2-yl)-
2, 5-diphenyl-tetrazolium bromide colorimetric assay
(MTT assay). The percentage of cells adhering was calcu-
lated as follows: % binding = (absorbance of treated sur-
face - ECM component)/absorbance of total surface ×
100. All experiments were performed in triplicate.
Invasion assay
I n v a s i o n  a c t i v i t y  o f  c a n c e r  c e l l s  w a s  m e a s u r e d  b y  t h e
method of Albini et al. [15] with some modifications.
Briefly, cancer cells (1 × 104/ml, 200 μl) were seeded in
the upper chamber separated with a 12-μm membrane
filter coated with 50 μg of Matrigel without adding extra-
cellular stimuli. After incubation for 72 h at 37°C, cancer
cells invading the lower chamber were manually counted
under a microscope. Six randomly selected fields were
counted for each assay. Mean values from six fields were
calculated as sample values. For each group, culture was
performed in triplicate.
RNA isolation and reverse transcription-polymerase chain 
reaction (RT-PCR)
Total RNA extraction and cDNA amplification were as
described previously [16]. The following oligonucleotides
were used for RT-PCR analysis: MUC5AC: 5'-TGCAC-
CTGTGACAGCAGGAT-3' (sense), 5'-ACCTCCACCT-
TCCTATGGCT-3' (anti-sense); integrin α3: 5'-
TACGTGCGAGGCAATGACCTA-3' (sense), 5'-TTTG-
GGGGTGCAGGATGAAGCT-3' (anti-sense); integrin
α9: 5'-AGAGGAGGAGAGGGAACTGC-3' (sense), 5'-
CCCAGACAGGTGGCTTGTAT-3' (anti-sense); integrin
β3: 5'-GGGGACTGCCTGTGTGACTC-3' (sense), 5'-
CTTTTCGGTCGTGGATGGTG-3' (anti-sense); MMP-
3: 5'-GATATAAATGGCATTCAGTCCCTC-3' (sense),
5'-TCCTTGCTAGTAACTTCATATGCG-3' (anti-sense);
and VEGF: 5'-CCTGGTGGACATCTTCCAGGAG-
TACC-3' (sense), 5'-GAAGCTCATCTCTCCTATGT-
GCTGGC-3'(anti-sense). The PCR condition as follows:
predenaturation, 94°C for 10 min, denaturation, 94°C for
50 sec, annealing, 59°C for 50 sec; extention, 72°C for 1
min and final incubation, 72°C for 7 min. Other primers
and PCR conditions were as described previously [16-19].
In vivo experiments
For subcutaneous tumorigenicity, 1 × 107 cancer cells
were injected into the flanks of BALB/c nude mice. For in
vivo liver metastasis, 7.5 × 105 cancer cells were injected
into the lower pole of the spleen under ether anesthesia.
Mice were sacrificed after 5 weeks in order to measure
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peritoneal dissemination, 1 × 107 each cancer cells were
injected into the peritoneal cavity, and the formation of
peritoneal metastases was examined. Mice were sacri-
ficed 14 days after injection, and peritoneal metastatic
nodules were counted.
Animal studies were performed in accordance with the
standard guidelines established by the Osaka City Univer-
sity Graduate School of Medicine. Six-week -old female
Balb/c nude mice (Oriental Kobo, T okyo, JAPAN) were
used in all experiments, and five mice were used in each
group.
Measurement of VEGF in cell culture supernatants
For the generation of conditioned media, 1 × 105 cells
were plated in a 6-well plate in growth medium and were
allowed to attach overnight at 37°C. After washing with
PBS, cells were moved to serum-free medium. After 24 h
of incubation, conditioned medium was collected and
VEGF concentrations were determined using a commer-
cial human VEGF-specific enzyme-linked immunosor-
bent assay (R&D Systems, USA).
Western blot analysis
Protein expression of VEGFR1, p-VEGFR1, MMP-3,
Erk1/2, p-ERK and alpha3-integrin was examined by
Western analysis. Cells grown to semiconfluence in 100-
mm dishes were lysed in lysis buffer containing 20 mM
Tris (pH 8.0), 137 mM EDTA, 100 mM NaF, 1 mM phe-
nylmethylsulfonyl fluoride, 0.25 trypsin inhibitory units/
ml aprotinin and 10 mg/ml leupeptin. Aliquots contain-
ing 50 μg of total protein were subjected to SDS-PAGE,
and the protein bands were transferred to a polyvi-
nylidene difluoride membrane (Amersham, Aylesbury,
UK). Membranes were blocked with 5% nonfat milk or
5% FBS in Tris-buffered saline containing 0.1% Tween 20
at room temperature for 1 h and then incubated over-
night at 4°C with mouse antihuman VEGF R1 antibody,
rabbit anti-phospho-VEGF R1 antibody (R&D systems),
mouse anti-MMP3 monoclonal antibody (MILLIPORE,
USA), rabbit Erk1/2 polyclonal antibody, mouse p-ERK
monoclonal antibody (SANTA CRUZ, USA), rabbit anti-
human integrin alpha3 polyclonal antibody (MILLI-
PORE, USA) and beta-actin antibody (Cell Signaling,
USA). After three washes, membranes were incubated for
1 h at room temperature with anti-mouse or rabbit IgG
horseradish peroxidase-linked species-specific whole
antibody (Amersham, USA). The three washes in TBST
were repeated, and then the immunoreactive protein was
detected using ImmunoStar Long Detection (WAKO,
Tokyo, JAPAN).
Statistical analysis
Student's t-test was used for statistical analysis. P values
of less than 0.05 were considered to indicate statistical
significance.
Results
Reduced expression of MUC5AC in SW1990 and BxPC3 cells
As Background, we tested MUC5AC expression in 100
specimens of pancreatic ductal carcinoma (Fig. 1).
MUC5AC protein was detected in 85% of patients with
pancreatic cancer, whereas no expression was observed in
normal ductal tubular cells. Then, to examine the func-
tion of MUC5AC in pancreatic cancer cells, we delivered
siRNA vector targeting MUC5AC into two human pan-
creatic cancer cells SW1990 and BxPC3 which were
expressed MUC5AC. The resulting stable cell line, si-
SW1990 and si-BxPC3, exhibited no expression of
MUC5AC mRNA (Fig. 2A). As negative control, we con-
firmed no MUC5AC expression in PCI-64 cell (Fig. 2A).
Also MUC5AC siRNA had no effect on the viability and
form of SW1990 as well as BxPC3. The proliferative prop-
erties of transfectants did not differ from those of the
parental cell lines (Fig. 2B). Doubling time of both cell
lines were about 13 hours.
Suppression of MUC5AC reduced the adhesive and invasive 
capacity of SW1990 and BxPC3 cells
Cancers grow through adhesion or invasion into intersti-
tial tissue via extracellular matrix components (ECM).
Then, we compared these properties between parental
cell lines and siRNA transfectants (si-SW1990, si-BxPC3).
We examined cellular adhesiveness to representative
ECM of Matrigel, laminine and fibronectin, and evalu-
ated cell viability si-SW1990 or si-BxPC3 adhering to
ECM. The number of viable si-SW1990 was significantly
reduced when compared with SW1990 (Fig. 3A). The
percentage of adhesion to Matrigel, laminin and fibronec-
tin decreased by 29% (P = 0.019), 22% (P = 0.008) and 34%
(P = 0.0002), respectively (Fig. 3B). si-BxPC3 also
Figure 1 Immunohistochemistry of MUC5AC. Paraffiin-embedded 
tissues were stained using MUC5AC monoclonal antibody. Represen-
tative fileld of tumor tissue among 100 specimens of pancreatic ductal 
carcinoma showed MUC5AC protein expression (brown) limited to tu-
mor epithelium. Scale bar, 50 μm.Yamazoe et al. Journal of Experimental & Clinical Cancer Research 2010, 29:53
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revealed decrease of adhesion to three ECMs compared
with BxPC3 (Fig. 3B). We then evaluated the invasive
activity of cancer cells by Matrigel invasion assay.
Through the 12-μm pore membrane, the number of
migratory si-SW1990 cells significantly decreased by 85%
compared with SW1990 (Fig. 4A, B). si-BxPC3 showed
similar reduction of invasion to ECMs (Fig. 4B).
Suppression of MUC5AC reduced expression of integrins 
and production of MMP-3 and VEGF
In order to clarify the underlying mechanisms of these
properties, we examined the mRNA expression of mole-
cules associated with cell adhesion and invasion by RT-
PCR. No differences were seen between SW1990 and si-
SW1990 with regard to mRNA expression of E-Cadherin,
Snail, ZO-1, ZO-2, MMPs and integrins, whereas mRNA
expression levels of α3, α9, and β3 integrin, MMP-3 and
VEGF had decreased in both of si-SW1990 as compared
with SW1990. si-BxPC3 also exhibited lower mRNA
expression of α3 integrin, MMP-3 and VEGF. No expres-
sion of VEGFR-2 and twist were detected (Fig. 5A). Next,
we investigated production of MMP-3 and alpha 3-integ-
rin proteins by cancer cells, resulting in higher expression
level of these proteins by parental cells compared with
MUC5AC suppressed cells (Fig. 5B). In addition, produc-
tion of VEGF was significantly lower in the culture super-
natant of si-SW1990 and si-BxPC3 (Fig. 5C). Having
demonstrated that SW1990 and si-SW1990 cell express
VEGFR-1 mRNA and produce VEGF, we finally exam-
ined phosphorylation of VEGFR-1 (p-VEGFR-1) and
Erk1/2 on both cell lines by western blot analysis. Fig. 5B
showed that VEGF induced VEGFR-1 phosphorylation
were higher in both of SW1990 and BxPC3 compared
with si-SW1990 and si-BxPC3. Moreover, Erk 1/2 phos-
phorylation was strongly reduced in MUC5AC reducing
cells. On the other hand, PCI-64 which has originally
expression of MUC5AC did not show mRNA expression
Figure 3 Effect of MUC5AC suppression on cell adhesion. (A) Can-
cer cells were seeded in 96-well plates coated with Matrigel, laminin 
and fibronectin. After 30 min incubation, adherent cells were quanti-
fied by MTT assay. A phase contrast photograph of SW-1990 shows the 
representative adhering cells to the well coated in finbonectin. Scale 
bar, 50 μm. (B) Quantitication of the effect of MUC5AC downregulation 
on cell adhesion to Matrigel, laminin and fibronectin. Cell adhesion of 
si-SW1990 and si-BxPC3 to ECM declined significantly compared with 
parental cells. Shown data are means ± SD. *; P < 0.05; **; P < 0.01; ***; 
P < 0.001.
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of genes up-regulated in SW1990 and BxPC3 or the phos-
phorylation of VEGF-R or Erk1/2. No activation of Akt
signaling was detected (data not shown).
Effects of MUC5AC inhibition on si-SW1990 cell in vivo
In order to evaluate in vivo effects, we examined subcuta-
neous tumorigenicity, liver metastasis and peritoneal dis-
semination. Mice receiving inoculation of si-SW1990
cells showed no subcutaneous tumorigenesis (0%, 0/5),
liver metastasis (0%, 0/5) or mesentery metastasis (0%, 0/
5). In c ontrast, these metastases were seen in all mice
inoculated with SW1990 (Fig. 6). As si-SW1990, inocula-
tion of si-BxPC3 did not establish subcutaneous xeno-
grafts in vivo.
Discussion
In this study, we have demonstrated that suppression of
MUC5AC which was commonly expressed in pancreatic
ductal carcinoma reduced adhesive, invasive and meta-
static potential of pancreatic cancer cell lines. These
results indicated that MUC5AC expression in cancer cells
might be associated with invasive progression of pancre-
atic ductal carcinoma. It has been reported that mucins
are associated with cancer growth. For example, MUC1
and MUC4 mucin augment cellular proliferation in vivo
[12,20]. In our study, proliferation rate was not affected,
although invasive and adhesive activities of SW1990 after
MUC5AC inhibition were decreased markedly, suggest-
ing that MUC5AC, similarly to MUC1 or MUC4, might
have potential to accelerate progression of pancreatic
cancer.
For cancer progression, several genes related to cell
attachment, proteolysis and angiogenesis are important.
We demonstrated that si-SW1990 reduced expression of
α3, α9 and β3 integrins and MMP-3. Another MUC5AC
down-regulated BxPC3 cells also decreased MMP-3, α3-
integrin and VEGF. These results were supported by
other reports. For example, Lohi reported that α3β1 inte-
grin was a probable cell surface receptor acting with lami-
nin-5 in the regulation of carcinoma cell invasion and
proliferation [21]. α9β1integrin can mediate accelerated
cell migration [22] and Hosotani demonstrated that α5β3
Figure 4 Effect of MUC5AC suppression on cell invasion. (A) Cell 
invasion through membrane filter coated with Matrigel was examined. 
72 h later, invading cancer cells were stained by hematoxylin and 
counted under a microscope. A phase contrast photograph of SW-
1990 shows the representative adhering cells to the well coated in fin-
bonectin (arrows). Scale bar, 50 μm. (B) The number of invading si-
SW1990 and si-BxPC3 was significantly lower compared to parental 
cells. Data shown are means ± SD. ***; P < 0.001.
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integrin expression is significantly correlated with lymph
node metastasis and advanced stages of pancreatic can-
cer[23]. MMP-3 plays a crucial role in the insidious inva-
siveness of astrocytoma [24]. These results suggested that
MUC5AC might augment malignant potential of pancre-
atic cancer cell such as MUC1 or MUC4. On the other
hands, we found that PCI-64 cells by which MUC5AC
was not originally expressed showed no augmentation of
MMP-3, α3-integrin or VEGF, indicating that MUC5AC
might not play a central role in progression of cancer like
PCI-64 cells which have low level expression of
MUC5AC.
Interestingly, we have observed significant decrease of
VEGF-A production and VEGF-R1 phosphorylation by
si-SW1990 and si-BxPC3 compared to parental cells.
VEGF, a potent angiogenic mitogen, is linked to tumor
growth, metastasis and poor prognosis for patients with
pancreatic adenocarcinoma [25-28]. Association of
VEGF with mucin has been reported. For example,
immunohistochemistry of a combination of MUC1,
VEGF and other two molecules was detected all ovarian
cancer [29]. In non-small cell lung cancer, VEGF expres-
sion and MUC1 expression were independent prognostic
variables [30]. Although we could not find reports about
relationship of VEGF with MUC5AC, our results sug-
gested that MUC5AC might have potential to regulate
VEGF expression by cancer cells themselves.
Several studies have shown correlation among integrin,
MMP and VEGF. An association between α5β3 integrin
and MMP-2 activation was demonstrated in melanoma
and breast cancer cells [23]. Expression of MMP-3 was
induced by VEGF treatment in human endothelial cells.
Recent studies have demonstrated that tumors and lymp-
hangiogenic growth factors, such as VEGF-A and VEGF-
C, induced lymphatic vessel expression of α4β1 integrin
[31]. Our results showed that MUC5AC down regulation
suppressed several integrins, MMP-3 and VEGF, indicat-
ing that down-regulated MUC5AC in pancreateic cancer
might reduce production of VEGF-A resulting in sup-
pression of integrins and MMP-3. However, our results
did not demonstrate direct evidence that MMP-3 and α3
integrin suppressed by MUC5AC downregulation were
associated with VEGF. Then we examined MAPK path-
ways in MUC5AC suppressed cells. Janes et al previously
reported that pancreatic carcinoma cell lines expressed
VEGFR-1, as well as VEGF and VEGFR-1 was capable of
increasing MAPK signaling, migration, and invasion in
an autocrine mechanism [32]. In this study, we have dem-
onstrated that p-VEGFR-1 and p-Erk 1/2 of parental cells
were down-regulated by MUC5AC suppressed cell lines.
VEGF-A induced signaling cascade is mediated via acti-
vation of both of VEGFR-1 and VEGFR-2. We did not
show phosphorylation of VEGF-R2 in this study, because
SW1990 expressed no VEGFR-2 mRNA. Thus, our
results suggest that MUC5AC positive pancreatic cancer
cells might be activated the invasive potential via VEGFR-
1 signaling pathway in an autocrine manner.
To clarify effect of MUC5AC on tumor, we tried to test
it using mouse model in vivo, because our in vitro study
has the limitation with regard to true tumor microenvi-
ronment. However, we found no subcutaneous tumori-
genesis, intraperitoneal metastasis or hepatic metastasis
after inoculation of MUC5AC suppressed cells. Several
studies have reported that VEGF is believed to be essen-
tial for growth and metastasis of solid malignancies in
vivo [27,33,34]. Fukusawa et al previously reported that
pancreatic tumor growth and metastasis in vivo were sig-
nificantly suppressed by a soluble VEGFR chimer which
binds VEGF-A with high affinity [35]. Although we
showed no direct evidence that MUC5AC was associated
with tumorigenesis of pancreatic tumor, it was likely that
inhibition of MUC5AC might reduce VEGF production
by tumor in vivo. For future study, it should be necessary
to investigate the mechanism for association of MUC5AC
with tumorigenesis in vivo.
Figure 6 Effects of MUC5AC suppression on SW1990 cell metasta-
sis in vivo. Images of subcutaneous xenograft, liver metastasis and 
peritoneal metastasis following inoculation of SW1990 or si-SW1990. 
SW-1990 but not si-SW1990 formed a large subcutaneous nodule, and 
numerous nodules in the liver and intraperitoneal cavity.
s
u
b
c
u
t
a
n
e
o
u
s
 
t
u
m
o
r
SW1990 si-SW1990
l
i
v
e
r
 
m
e
t
a
s
t
a
s
i
s
i
n
t
r
a
p
e
r
i
t
o
n
e
a
l
 
m
e
t
a
s
t
a
s
i
sYamazoe et al. Journal of Experimental & Clinical Cancer Research 2010, 29:53
http://www.jeccr.com/content/29/1/53
Page 7 of 8
Conclusions
The present work is the first demonstration of an associa-
tion of MUC5AC with pancreatic cancer cell invasion.
MUC5AC might contribute to the progression of pancre-
atic cancer by inducing adhesiveness and invasiveness in
ECM via VEGF overexpression, indicating that MUC5AC
may be a potentially target in the treatment of pancreatic
cancer.
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